163 related articles for article (PubMed ID: 31543370)
1. Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.
Nanni L; Pellegrini C; Stefoni V; Argnani L; Cavo M; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e595-e596. PubMed ID: 31543370
[No Abstract] [Full Text] [Related]
2. [Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
Calleja A; Bouclet F
Bull Cancer; 2021 Jan; 108(1):12-13. PubMed ID: 33308986
[No Abstract] [Full Text] [Related]
3. Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma.
Wolf S; Goiriz R; Dhairyawan R; Paige D; Rizvi H; Haroon A; Montoto S
Clin Exp Dermatol; 2019 Jul; 44(5):562-564. PubMed ID: 30430604
[No Abstract] [Full Text] [Related]
4. FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
Milunović V; Mišura Jakobac K; Kursar M; Mandac Rogulj I; Ostojić Kolonić S
Eur J Haematol; 2019 Sep; 103(3):145-151. PubMed ID: 31166030
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.
Poston JN; Fromm JR; Rasmussen HA; Shustov AR; Libby EN; Smith SD; Gooley T; Gopal AK
Br J Haematol; 2019 Jul; 186(1):159-162. PubMed ID: 30592026
[No Abstract] [Full Text] [Related]
7. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.
Şahin M; Miskioğlu M; İnanır I; Akar H; Neşe N; Temiz P; Aydoğdu İ
Turk J Haematol; 2021 Feb; 38(1):85-87. PubMed ID: 33504137
[No Abstract] [Full Text] [Related]
8. Long-term Remission by Brentuximab Vedotin for Non-mediastinal Gray Zone Lymphoma Refractory to Autologous Stem Cell Transplantation.
Ebisawa K; Masamoto Y; Koya J; Shimura A; Shinozaki-Ushiku A; Toyama K; Nakazaki K; Kurokawa M
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e602-e604. PubMed ID: 31551171
[No Abstract] [Full Text] [Related]
9. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
[TBL] [Abstract][Full Text] [Related]
12. Mycosis fungoides, Psoriasis and Anti-PD-1 - A New Aspect of Known Associations.
Geller S; Pulitzer M; Horwitz SM; Moskowitz AJ; Myskowski PL
J Dtsch Dermatol Ges; 2019 Feb; 17(2):186-188. PubMed ID: 30549439
[No Abstract] [Full Text] [Related]
13. Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report.
Arroyo-Andrés J; Agud-Dios M; Rubio-Muniz CA; Vico-Alonso C; Cortijo-Cascajares S; Ortiz-Romero PL
Int J Dermatol; 2022 Jul; 61(7):e267-e269. PubMed ID: 34363613
[No Abstract] [Full Text] [Related]
14. Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.
Kim Y; Sudo A; Oyama R; Keino D; Tomizawa D; Kato M; Osumi T; Mori T
J Pediatr Hematol Oncol; 2021 Aug; 43(6):e864-e866. PubMed ID: 32769561
[TBL] [Abstract][Full Text] [Related]
15. Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis.
Gao S; Zhang M; Wu K; Zhu J; He Z; Li J; Chen C; Qiu K; Yu X; Wu J
Expert Opin Drug Saf; 2020 May; 19(5):617-623. PubMed ID: 31955620
[No Abstract] [Full Text] [Related]
16. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
17. Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
Halligan SJ; Grainge MJ; Martinez-Calle N; Fox CP; Bishton MJ
Br J Haematol; 2022 Feb; 196(4):932-938. PubMed ID: 34664265
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C; Dickinson M; Whisstock J; Prince HM
Expert Rev Hematol; 2019 Jan; 12(1):5-19. PubMed ID: 30526166
[TBL] [Abstract][Full Text] [Related]
19. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A; Pirrie SJ; Linton K; Warbey V; Paterson K; Davies AJ; Collins GP; Menne T; McKay P; Fields PA; Miall FM; Nagy E; Wheatley K; Reed R; Baricevic-Jones I; Barrington S; Radford J
Br J Haematol; 2021 Apr; 193(1):63-71. PubMed ID: 32926420
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions related to brentuximab vedotin use: A real-life retrospective study.
Clarivet B; Vincent L; Vergely L; Bres V; Foglia K; Cartron G; Hillaire-Buys D; Faillie JL
Therapie; 2019 Jun; 74(3):343-346. PubMed ID: 30177280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
